Dobutamine
From Wikipedia, the free encyclopedia
| |
| Dobutamine
| |
| Systematic (IUPAC) name | |
| 4-[2-[3-(4-hydroxyphenyl)-1-methyl-propyl] aminoethyl]benzene-1,2-diol | |
| Identifiers | |
| CAS number | 34368-04-2 |
| ATC code | C01CA07 |
| PubChem | 36811 |
| DrugBank | APRD00122 |
| Chemical data | |
| Formula | C18H23NO3 |
| Mol. weight | 301.38 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 2 minutes |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Dobutamine is a beta-1 adrenergic agonist. It is a direct-acting agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart, increasing contractility and cardiac output. Since it does not act on dopamine receptors to induce the release of norepinephrine (an alpha-1 agonist), dobutamine is less prone to induce hypertension than dopamine. Chronotropic, arrhythmogenic, and vasodilative effects are negligible. Dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility, which could be the result of either organic heart disease or cardiac surgical procedures.
| Adrenergic and dopaminergic agents (C01CA)edit | ||
|---|---|---|
|
Dobutamine, Dopamine, Epinephrine, Fenoldopam, Isoprenaline, Metaraminol, Midodrine, Norepinephrine, Octopamine, Phenylephrine | ||
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
